{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:42:15Z","timestamp":1786984935040,"version":"build-2736575974"},"reference-count":223,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.autrev.2023.103404","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T11:52:37Z","timestamp":1691063557000},"page":"103404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["From systemic lupus erythematosus to lupus nephritis: The evolving road to targeted therapies"],"prefix":"10.1016","volume":"22","author":[{"given":"Marc","family":"Xipell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema M.","family":"Lled\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson C.","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Tamirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Serrano","family":"del Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"G\u00f3mez-Puerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Garc\u00eda-Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.W.","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Houssiau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0005","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"16","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2023.103404_bb0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clim.2016.09.012","article-title":"Genetics of human lupus nephritis","volume":"185","author":"Iwamoto","year":"2017","journal-title":"Clin Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb0020","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm.2752","article-title":"Taming lupus-a new understanding of pathogenesis is leading to clinical advances","volume":"18","author":"Liu","year":"2012","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.autrev.2023.103404_bb0025","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013010026","article-title":"The Pathogenesis of Lupus Nephritis","volume":"24","author":"Lech","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"6881","key":"10.1016\/j.autrev.2023.103404_bb0030","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/416603a","article-title":"Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors","volume":"416","author":"Leadbetter","year":"2002","journal-title":"Nature."},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/cei.12877","article-title":"DNA methylation alterations in the pathogenesis of lupus","volume":"187","author":"Chen","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2023.103404_bb0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clim.2016.08.010","article-title":"Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis","volume":"185","author":"Mistry","year":"2017","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.cdd.4400460","article-title":"Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease","volume":"6","author":"Rosen","year":"1999","journal-title":"Cell Death Differ"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0889-857X(05)70136-8","article-title":"Apoptosis in systemic lupus erythematosus. Clinical implications","volume":"26","author":"Andrade","year":"2000","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2023.103404_bb0055","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fimmu.2014.00164","article-title":"Breaking immunological tolerance in systemic lupus erythematosus","volume":"5","author":"Pieterse","year":"2014","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0060","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41423-020-00630-3","article-title":"Necroptosis, pyroptosis and apoptosis: an intricate game of cell death","volume":"18","author":"Bertheloot","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0065","doi-asserted-by":"crossref","first-page":"167378","DOI":"10.1016\/j.jmb.2021.167378","article-title":"Apoptosis, pyroptosis, and necroptosis-oh my! The many ways a cell can die","volume":"434","author":"Ketelut-Carneiro","year":"2022","journal-title":"J Mol Biol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103404_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103211","article-title":"Macrophages in Lupus Nephritis: Exploring a potential new therapeutic avenue","volume":"21","author":"Kwant","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2023.103404_bb0075","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nri2358","article-title":"Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases","volume":"8","author":"Gilliet","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2023.103404_bb0080","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000368581","article-title":"Lupus nephritis: From pathogenesis to targets for biologic treatment","volume":"128","author":"Liu","year":"2014","journal-title":"Nephron Clin Pract"},{"issue":"87","key":"10.1016\/j.autrev.2023.103404_bb0085","first-page":"123","article-title":"Interferon-\u03b3 and systemic autoimmunity","volume":"16","author":"Pollard","year":"2013","journal-title":"Discov Med"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/jir.2010.0126","article-title":"Systems biology of interferon responses","volume":"31","author":"Hertzog","year":"2011","journal-title":"J Interferon Cytokine Res"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0095","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.immuni.2006.08.010","article-title":"Type I interferon in systemic lupus erythematosus and other autoimmune diseases","volume":"25","author":"Banchereau","year":"2006","journal-title":"Immunity."},{"key":"10.1016\/j.autrev.2023.103404_bb0100","doi-asserted-by":"crossref","first-page":"6533","DOI":"10.2147\/JIR.S363722","article-title":"Lupus nephritis: current perspectives and moving forward","volume":"15","author":"Lichtnekert","year":"2022","journal-title":"J Inflamm Res"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0105","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/BOR.0b013e32832e089e","article-title":"Type I interferon and lupus","volume":"21","author":"R\u00f6nnblom","year":"2009","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1074-7613(03)00208-5","article-title":"Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6","volume":"19","author":"Jego","year":"2003","journal-title":"Immunity."},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0115","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/intimm\/dxh227","article-title":"IFN{alpha} enhances human B-cell chemotaxis by modulating ligand-induced chemokine receptor signaling and internalization","volume":"17","author":"Badr","year":"2005","journal-title":"Int Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0120","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.4049\/jimmunol.0801607","article-title":"Type I interferon (IFN alpha) acts directly on human memory CD4+ T cells altering their response to antigen","volume":"183","author":"Gallagher","year":"2009","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0125","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nm1590","article-title":"TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity","volume":"13","author":"Baccala","year":"2007","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.smim.2011.01.009","article-title":"The type I interferon system in the development of lupus","volume":"23","author":"R\u00f6nnblom","year":"2011","journal-title":"Semin Immunol"},{"key":"10.1016\/j.autrev.2023.103404_bb0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.0105-2896.2005.00252.x","article-title":"Interferons as pathogenic effectors in autoimmunity","volume":"204","author":"Baccala","year":"2005","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cytogfr.2007.10.006","article-title":"Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history","volume":"19","author":"Fitzgerald-Bocarsly","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0145","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrneph.2011.197","article-title":"A novel pathogenetic concept-antiviral immunity in lupus nephritis","volume":"8","author":"Migliorini","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0150","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/art.30187","article-title":"Network analysis of associations between serum interferon-\u03b1 activity, autoantibodies, and clinical features in systemic lupus erythematosus","volume":"63","author":"Weckerle","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103404_bb0155","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus","volume":"67","author":"Postal","year":"2020","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103404_bb0160","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/08916930310001625952","article-title":"Microarray analysis of interferon-regulated genes in SLE","volume":"36","author":"Crow","year":"2003","journal-title":"Autoimmunity."},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0165","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.autrev.2023.103404_bb0170","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/annrheumdis-2018-213485","article-title":"Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis","volume":"77","author":"Pamfil","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0175","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/13543784.2016.1162291","article-title":"Drugs in early clinical development for Systemic Lupus Erythematosus","volume":"25","author":"Postal","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0180","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/1756-185X.13817","article-title":"State-of-the-art treatment of systemic lupus erythematosus","volume":"23","author":"Tanaka","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0185","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic Lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0190","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/BOR.0000000000000577","article-title":"Neutrophils in lupus nephritis","volume":"31","author":"Nishi","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"5663","key":"10.1016\/j.autrev.2023.103404_bb0195","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science."},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0200","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1083\/jcb.200606027","article-title":"Novel cell death program leads to neutrophil extracellular traps","volume":"176","author":"Fuchs","year":"2007","journal-title":"J Cell Biol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103404_bb0205","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1056\/NEJMcibr1107085","article-title":"Systemic lupus erythematosus and the neutrophil","volume":"365","author":"Bosch","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0210","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ekir.2018.11.005","article-title":"Clinical Implications of Excessive Neutrophil Extracellular Trap Formation in Renal Autoimmune Diseases","volume":"4","author":"van Dam","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0215","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.rdc.2021.04.002","article-title":"Neutrophil dysregulation in the pathogenesis of systemic Lupus Erythematosus","volume":"47","author":"Liu","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"issue":"73","key":"10.1016\/j.autrev.2023.103404_bb0220","doi-asserted-by":"crossref","first-page":"73ra19","DOI":"10.1126\/scitranslmed.3001180","article-title":"Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus","volume":"3","author":"Lande","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2023.103404_bb0225","first-page":"8","article-title":"Acetylated histones in apoptotic microparticles drive the formation of neutrophil extracellular traps in active lupus nephritis","volume":"14","author":"Rother","year":"2017","journal-title":"Front Immunol"},{"issue":"73","key":"10.1016\/j.autrev.2023.103404_bb0230","doi-asserted-by":"crossref","first-page":"73ra20","DOI":"10.1126\/scitranslmed.3001201","article-title":"Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus","volume":"3","author":"Garcia-Romo","year":"2011","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0235","first-page":"653","article-title":"Neutrophils from systemic lupus erythematosus patients demonstrate increased nuclear DNA damage","volume":"20","author":"McConnell","year":"2002","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0240","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/ard.58.5.309","article-title":"Increased apoptotic peripheral blood neutrophils in systemic lupus erythematosus: relations with disease activity, antibodies to double stranded DNA, and neutropenia","volume":"58","author":"Courtney","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103404_bb0245","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3389\/fimmu.2017.01136","article-title":"Acetylated histones in apoptotic microparticles drive the formation of neutrophil extracellular traps in active lupus nephritis","volume":"8","author":"Rother","year":"2017","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0250","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell."},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0255","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nm.4027","article-title":"Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease","volume":"22","author":"Lood","year":"2016","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb0260","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.kint.2018.08.035","article-title":"Extracellular traps in kidney disease","volume":"94","author":"Nakazawa","year":"2018","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0265","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/BOR.0000000000000777","article-title":"Cellular aspects of the pathogenesis of lupus nephritis","volume":"33","author":"Chang","year":"2021","journal-title":"Curr Opin Rheumatol"},{"issue":"24","key":"10.1016\/j.autrev.2023.103404_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms20246231","article-title":"B cell abnormalities in systemic lupus erythematosus and lupus nephritis\u2014role in pathogenesis and effect of immunosuppressive treatments","volume":"20","author":"Yap","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0275","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cellimm.2006.04.007","article-title":"Regulation of peripheral B cell maturation","volume":"239","author":"Thomas","year":"2006","journal-title":"Cell Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0280","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.smim.2005.11.002","article-title":"Initiation of pre-B cell receptor signaling: common and distinctive features in human and mouse","volume":"18","author":"Espeli","year":"2006","journal-title":"Semin Immunol"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2023.103404_bb0285","first-page":"47","article-title":"Human peripheral blood B-Cell compartments: A crossroad in B-cell traffic","volume":"78","author":"Perez-Andres","year":"2010","journal-title":"Cytom Part B - Clin Cytom"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0290","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jim.2010.06.009","article-title":"Abnormalities of B cell subsets in patients with systemic lupus erythematosus","volume":"363","author":"D\u00f6rner","year":"2011","journal-title":"J Immunol Methods"},{"issue":"Suppl. 5","key":"10.1016\/j.autrev.2023.103404_bb0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3909","article-title":"Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity","volume":"14","author":"Mei","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0300","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2023.103404_bb0305","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3389\/fimmu.2018.00427","article-title":"Plasma Cell Differentiation Pathways in Systemic Lupus Erythematosus","volume":"9","author":"Malkiel","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0310","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-065X.2010.00938.x","article-title":"Memory B and memory plasma cells","volume":"237","author":"Yoshida","year":"2010","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0315","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jaci.2013.01.046","article-title":"B-cell biology and development","volume":"131","author":"Pieper","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103404_bb0320","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nrrheum.2009.141","article-title":"B-cell-directed therapies for autoimmune disease","volume":"5","author":"D\u00f6rner","year":"2009","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103404_bb0325","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0330","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ndt\/gfy267","article-title":"B-cell therapy in lupus nephritis: an overview","volume":"34","author":"Almaani","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"6781","key":"10.1016\/j.autrev.2023.103404_bb0335","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0340","article-title":"B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools","volume":"9","author":"Parodis","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.autrev.2023.103404_bb0345","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-receptor in B cell selection and survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0350","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0355","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/nep.12047","article-title":"The role of cytokines in the pathogenesis of systemic lupus erythematosus - from bench to bedside","volume":"18","author":"Yap","year":"2013","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0360","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/art.27189","article-title":"Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study","volume":"62","author":"Jacobi","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0365","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.autrev.2023.103404_bb0370","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri1886","article-title":"Competence and competition: The challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0375","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/art.40396","article-title":"Review: abnormal B cell development in systemic Lupus Erythematosus: what the genetics tell us","volume":"70","author":"Karrar","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3433","article-title":"Mechanisms of B cell autoimmunity in SLE","volume":"13","author":"D\u00f6rner","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103404_bb0385","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3389\/fimmu.2019.01028","article-title":"Sources of pathogenic nucleic acids in systemic Lupus Erythematosus","volume":"10","author":"Mustelin","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0390","doi-asserted-by":"crossref","DOI":"10.1186\/ar2780","article-title":"B cells in autoimmunity","volume":"11","author":"D\u00f6rner","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0395","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clim.2006.08.016","article-title":"Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE","volume":"122","author":"Vallerskog","year":"2007","journal-title":"Clin Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2023.103404_bb0400","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.autrev.2023.103404_bb0405","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1084\/jem.20040168","article-title":"Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB\/W mice","volume":"199","author":"Hoyer","year":"2004","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0410","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/art.24341","article-title":"A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.autrev.2023.103404_bb0415","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/ard.2006.067124","article-title":"B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response","volume":"66","author":"Ng","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2023.103404_bb0420","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/art.41703","article-title":"Molecular signatures of kidney antibody-secreting cells in lupus patients with active nephritis upon immunosuppressive therapy","volume":"73","author":"Crickx","year":"2021","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0425","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0430","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/intimm\/dxy081","article-title":"Thymus machinery for T-cell selection","volume":"31","author":"Kondo","year":"2019","journal-title":"Int Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0435","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/08916934.2019.1693545","article-title":"Th1, Th2, and Th17 cytokines in systemic lupus erythematosus","volume":"53","author":"Muhammad Yusoff","year":"2020","journal-title":"Autoimmunity"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb0440","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1172\/JCI78087","article-title":"T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity","volume":"125","author":"Moulton","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2023.103404_bb0445","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3389\/fimmu.2018.01088","article-title":"Aberrant T cell signaling and subsets in systemic lupus erythematosus","volume":"9","author":"Katsuyama","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103404_bb0450","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.681062","article-title":"Strategies to use nanoparticles to generate CD4 and CD8 regulatory T cells for the treatment of SLE and other autoimmune diseases","volume":"12","author":"Horwitz","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0455","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cyto.2014.09.011","article-title":"T cell subsets and their signature cytokines in autoimmune and inflammatory diseases","volume":"74","author":"Raphael","year":"2015","journal-title":"Cytokine."},{"key":"10.1016\/j.autrev.2023.103404_bb0460","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coi.2016.09.001","article-title":"T cells in systemic lupus erythematosus","volume":"43","author":"Su\u00e1rez-Fueyo","year":"2016","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0465","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.semarthrit.2004.07.002","article-title":"Autoantibody explosion in systemic lupus erythematosus: More than 100 different antibodies found in SLE patients","volume":"34","author":"Sherer","year":"2004","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0470","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2215\/CJN.05780616","article-title":"Update on lupus nephritis","volume":"12","author":"Almaani","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0475","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.ackd.2019.08.007","article-title":"Lupus nephritis and kidney transplantation: where are we today?","volume":"26","author":"Wong","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb0480","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0485","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005792-199303000-00005","article-title":"Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus","volume":"72","author":"Cervera","year":"1993","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.autrev.2023.103404_bb0490","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/ndt\/gfv381","article-title":"Sustained remission in lupus nephritis: still a hard road ahead","volume":"31","author":"Quintana","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0495","first-page":"713","article-title":"Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95","volume":"31","author":"Bj\u00f6rn\u00e5dal","year":"2004","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0500","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/art.1780380218","article-title":"Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes","volume":"38","author":"Ward","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0505","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.2353\/ajpath.2009.080585","article-title":"Viral RNA induces type I interferon-dependent cytokine release and cell death in mesangial cells via melanoma-differentiation-associated gene-5: Implications for viral infection-associated glomerulonephritis","volume":"175","author":"Fl\u00fcr","year":"2009","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0510","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1681\/ASN.2008010112","article-title":"Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes","volume":"20","author":"Mortensen","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0515","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/08916930903305633","article-title":"Pure anti-dsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB\/c mice","volume":"43","author":"Fenton","year":"2010","journal-title":"Autoimmunity."},{"issue":"12","key":"10.1016\/j.autrev.2023.103404_bb0520","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1136\/ard.2007.070482","article-title":"Nucleosomes possess a high affinity for glomerular laminin and collagen IV and bind nephritogenic antibodies in murine lupus-like nephritis","volume":"66","author":"Mjelle","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2023.103404_bb0525","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1681\/ASN.2014050493","article-title":"Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): Planted antigens","volume":"26","author":"Bruschi","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"April","key":"10.1016\/j.autrev.2023.103404_bb0530","first-page":"8","article-title":"IFN-I mediates lupus nephritis from the beginning to renal fibrosis","volume":"12","author":"Ding","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0535","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41584-020-0401-9","article-title":"Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy","volume":"16","author":"Maria","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb0540","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/exostosin 2\u2013associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0545","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.kint.2023.01.001","article-title":"Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry","volume":"103","author":"Caza","year":"2023","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.autrev.2023.103404_bb0550","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1136\/ard-2022-222620","article-title":"Dissecting the histological features of lupus nephritis highlights new common patterns of injury in class III\/IV","volume":"81","author":"Bolognesi","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0555","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0560","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10157-005-0357-8","article-title":"Mechanisms of immune-deposit formation and the mediation of immune renal injury","volume":"9","author":"Nangaku","year":"2005","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0565","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.2353\/ajpath.2009.090182","article-title":"Double-stranded DNA activates glomerular endothelial cells and enhances albumin permeability via a toll-like receptor-independent cytosolic DNA recognition pathway","volume":"175","author":"H\u00e4gele","year":"2009","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.autrev.2023.103404_bb0570","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.4049\/jimmunol.0900742","article-title":"Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis","volume":"183","author":"Fairhurst","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2023.103404_bb0575","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/139365","article-title":"Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: getting to know the unknown","volume":"2012","author":"Yung","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0580","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1681\/ASN.2010121301","article-title":"Macrophages in kidney repair and regeneration","volume":"22","author":"Duffield","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0585","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrrheum.2015.159","article-title":"What is damaging the kidney in lupus nephritis?","volume":"12","author":"Davidson","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2023.103404_bb0590","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1172\/JCI36150","article-title":"Macrophage diversity in renal injury and repair","volume":"118","author":"Ricardo","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2023.103404_bb0595","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3389\/fimmu.2014.00514","article-title":"From monocytes to M1\/M2 macrophages: phenotypical vs. functional differentiation","volume":"5","author":"Italiani","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103404_bb0600","doi-asserted-by":"crossref","first-page":"13","DOI":"10.12703\/P6-13","article-title":"The M1 and M2 paradigm of macrophage activation: time for reassessment","volume":"6","author":"Martinez","year":"2014","journal-title":"F1000Prime Rep"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0605","first-page":"138","article-title":"Macrophage phenotype in kidney injury and repair","volume":"1","author":"Meng","year":"2015","journal-title":"Kidney Dis (Basel, Switzerland)"},{"issue":"18","key":"10.1016\/j.autrev.2023.103404_bb0610","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13075-016-0989-y","article-title":"CD163+ M2c-like macrophages predominate in renal biopsies from patients with lupus nephritis","volume":"18","author":"Olmes","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0615","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.semnephrol.2010.03.003","article-title":"Macrophages and immunologic inflammation of the kidney","volume":"30","author":"Duffield","year":"2010","journal-title":"Semin Nephrol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0620","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1523-1755.2001.00492.x","article-title":"Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages","volume":"59","author":"Hill","year":"2001","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0625","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.4049\/jimmunol.1001983","article-title":"In situ B Cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis","volume":"186","author":"Chang","year":"2011","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0630","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1681\/ASN.2010050536","article-title":"The emergence of Th17 cells as effectors of renal injury","volume":"22","author":"Kitching","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0635","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/modpathol.2010.184","article-title":"Intrarenal production of B-cell survival factors in human lupus nephritis","volume":"24","author":"Neusser","year":"2011","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0640","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1681\/ASN.2010050515","article-title":"Local renal autoantibody production in lupus nephritis","volume":"22","author":"Espeli","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0645","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on lupus nephritis: core curriculum 2020","volume":"76","author":"Parikh","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1016\/j.autrev.2023.103404_bb0650","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","article-title":"The immune cell landscape in kidneys of patients with lupus nephritis","volume":"20","author":"Arazi","year":"2019","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2023.103404_bb0655","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11926-017-0708-y","article-title":"Renal macrophages and dendritic cells in SLE nephritis","volume":"19","author":"Maria","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"10.1016\/j.autrev.2023.103404_bb0660","doi-asserted-by":"crossref","first-page":"F1391","DOI":"10.1152\/ajprenal.00318.2013","article-title":"Increased tubulointerstitial recruitment of human CD141(hi) CLEC9A(+) and CD1c(+) myeloid dendritic cell subsets in renal fibrosis and chronic kidney disease","volume":"305","author":"Kassianos","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0665","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/BOR.0000000000000577","article-title":"Neutrophils in lupus nephritis","volume":"31","author":"Nishi","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0670","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41584-020-0401-9","article-title":"Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy","volume":"16","author":"Maria","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2023.103404_bb0675","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/ki.2010.13","article-title":"Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system","volume":"77","author":"Yu","year":"2010","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0680","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/ki.1975.47","article-title":"Interstitial immune complex nephritis in patients with systemic lupus erythematosus","volume":"7","author":"Brentjens","year":"1975","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb0685","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s40620-021-01007-z","article-title":"The extent of tubulointerstitial inflammation is an independent predictor of renal survival in lupus nephritis","volume":"34","author":"Gomes","year":"2021","journal-title":"J Nephrol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.103014","article-title":"Assessing and counteracting fibrosis is a cornerstone of the treatment of CKD secondary to systemic and renal limited autoimmune disorders","volume":"21","author":"de Cos","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0695","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1172\/JCI38399","article-title":"Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury","volume":"119","author":"Heymann","year":"2009","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.autrev.2023.103404_bb0700","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.4049\/jimmunol.1003010","article-title":"A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis","volume":"186","author":"Bethunaickan","year":"2011","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0705","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.semnephrol.2015.08.007","article-title":"The pathogenesis and therapeutic implications of tubulointerstitial inflammation in human lupus nephritis","volume":"35","author":"Clark","year":"2015","journal-title":"Semin Nephrol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0710","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1046\/j.1523-1755.2001.00017.x","article-title":"Proteinuria and tubulointerstitial lesions in lupus nephritis","volume":"60","author":"Hill","year":"2001","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0715","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002686","article-title":"Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I\/II trial","volume":"8","author":"Wang","year":"2022","journal-title":"RMD Open"},{"issue":"15","key":"10.1016\/j.autrev.2023.103404_bb0720","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.autrev.2023.103404_bb0725","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0730","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/MNH.0000000000000596","article-title":"The glomerular crescent: triggers, evolution, resolution, and implications for therapy","volume":"29","author":"Anguiano","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.autrev.2023.103404_bb0735","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1600-065X.2008.00630.x","article-title":"Development of TLR inhibitors for the treatment of autoimmune diseases","volume":"223","author":"Barrat","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2023.103404_bb0740","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2018.07.003","article-title":"Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition","volume":"195","author":"Torigoe","year":"2018","journal-title":"Clin Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb0745","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/art.24538","article-title":"Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort","volume":"61","author":"Pons-Estel","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0750","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb0755","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3899\/jrheum.120572","article-title":"The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus","volume":"40","author":"Akhavan","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103404_bb0760","first-page":"1","article-title":"Update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"2020","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0765","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.kint.2016.12.025","article-title":"The Case | Myeloid bodies in the kidney biopsy of a patient with systemic lupus erythematosus","volume":"92","author":"Bojic","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.autrev.2023.103404_bb0770","article-title":"Hydroxychloroquine-induced mimic of renal Fabry disease","volume":"94(3):634","author":"Sperati","year":"2018","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.autrev.2023.103404_bb0775","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/ndt\/gfaa267","article-title":"Steroids as treatment for glomerulonephritis: time for a rethink","volume":"37","author":"Hendra","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb0780","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/ndt\/gfv102","article-title":"Lupus nephritis management guidelines compared","volume":"31","author":"Wilhelmus","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.autrev.2023.103404_bb0785","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1093\/rheumatology\/keab347","article-title":"Prednisone in systemic lupus erythematosus: taper quickly, withdraw slowly","volume":"60","author":"Ruiz-Irastorza","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.autrev.2023.103404_bb0790","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092709","article-title":"Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues","volume":"9","author":"Porta","year":"2020","journal-title":"J Clin Med"},{"issue":"12","key":"10.1016\/j.autrev.2023.103404_bb0795","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"issue":"10289","key":"10.1016\/j.autrev.2023.103404_bb0800","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.autrev.2023.103404_bb0805","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb0810","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/ndt\/gfv102","article-title":"Lupus nephritis management guidelines compared","volume":"31","author":"Wilhelmus","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1016\/j.autrev.2023.103404_bb0815","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1084\/jem.20040168","article-title":"Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB\/W mice","volume":"199","author":"Hoyer","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2023.103404_bb0820","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13075-015-0603-8","article-title":"Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus","volume":"17","author":"Fassbinder","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0825","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"10.1016\/j.autrev.2023.103404_bb0830","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.autrev.2023.103404_bb0835","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group","volume":"343","author":"Chan","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0840","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103404_bb0845","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clim.2016.09.002","article-title":"Anti-dsDNA antibodies and resident renal cells \u2014 Their putative roles in pathogenesis of renal lesions in lupus nephritis","volume":"185","author":"Yung","year":"2017","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0850","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2249.2009.04051.x","article-title":"Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help","volume":"159","author":"Heidt","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2023.103404_bb0855","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3389\/fimmu.2018.01184","article-title":"The calcineurin inhibitor tacrolimus specifically suppresses human T follicular helper cells","volume":"9","author":"Wallin","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0860","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3109\/0886022X.2016.1148936","article-title":"Tacrolimus restores podocyte injury and stabilizes the expression of Cabin1 in 5\/6 nephrectomized rats","volume":"38","author":"Wen","year":"2016","journal-title":"Ren Fail"},{"issue":"11","key":"10.1016\/j.autrev.2023.103404_bb0865","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202101052R","article-title":"Tacrolimus ameliorates podocyte injury by restoring FK506 binding protein 12 (FKBP12) at actin cytoskeleton","volume":"35","author":"Yasuda","year":"2021","journal-title":"FASEB J"},{"key":"10.1016\/j.autrev.2023.103404_bb0870","doi-asserted-by":"crossref","first-page":"27915","DOI":"10.1038\/srep27915","article-title":"Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling","volume":"6","author":"Rodrigues-Diez","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0875","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0880","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.2008060665","article-title":"Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy","volume":"20","author":"Austin","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.autrev.2023.103404_bb0885","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/0961203310371155","article-title":"Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study","volume":"19","author":"Zavada","year":"2010","journal-title":"Lupus."},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0890","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5414\/CN109325","article-title":"Cyclosporine for the treatment of lupus nephritis in patients with systemic lupus erythematosus","volume":"89","author":"Yang","year":"2018","journal-title":"Clin Nephrol"},{"issue":"5 Suppl 6","key":"10.1016\/j.autrev.2023.103404_bb0895","first-page":"36","article-title":"Effect of FK-506 on human mixed lymphocyte reaction in vitro","volume":"19","author":"Kino","year":"1987","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb0900","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1681\/ASN.V1061366","article-title":"Newer immunosuppressive drugs: a review","volume":"10","author":"Gummert","year":"1999","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0905","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/ndt\/gfab022","article-title":"Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE","volume":"37","author":"van Gelder","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"20","key":"10.1016\/j.autrev.2023.103404_bb0910","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0915","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","article-title":"Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis","volume":"75","author":"Tamirou","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0920","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0162-3109(83)90032-2","article-title":"The effect of azathioprine on terminal differentiation of human B lymphocytes","volume":"6","author":"G\u00f3rski","year":"1983","journal-title":"Immunopharmacology."},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0925","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","article-title":"A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis","volume":"101","author":"Rovin","year":"2022","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb0930","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.4049\/jimmunol.173.5.3524","article-title":"Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus","volume":"173","author":"Ramanujam","year":"2004","journal-title":"J Immunol"},{"issue":"40","key":"10.1016\/j.autrev.2023.103404_bb0935","doi-asserted-by":"crossref","first-page":"15517","DOI":"10.1073\/pnas.0807841105","article-title":"BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact","volume":"105","author":"Scholz","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb0940","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.4049\/jimmunol.180.6.3655","article-title":"Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF andIL","volume":"180","author":"Benson","year":"2008","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2023.103404_bb0945","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1172\/JCI26385","article-title":"Similarities and differences between selective and nonselective BAFF blockade in murine SLE","volume":"116","author":"Ramanujam","year":"2006","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0950","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb0955","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb0960","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb0965","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: danger ahead?","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0970","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103404_bb0975","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/ndt\/gfaa117","article-title":"Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results","volume":"36","author":"Kraaij","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb0980","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1177\/0961203320965707","article-title":"Next stop in the treatment of refractory systemic lupus erythematosus: B-cell targeted combined therapy","volume":"30","author":"Bela","year":"2021","journal-title":"Lupus."},{"issue":"9","key":"10.1016\/j.autrev.2023.103404_bb0985","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/0961203316686703","article-title":"The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis","volume":"26","author":"Zhang","year":"2017","journal-title":"Lupus."},{"issue":"7","key":"10.1016\/j.autrev.2023.103404_bb0990","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb0995","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0961203319896018","article-title":"Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience","volume":"29","author":"Segarra","year":"2020","journal-title":"Lupus."},{"key":"10.1016\/j.autrev.2023.103404_bb1000","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.2147\/DDDT.S212500","article-title":"Clinical application of obinutuzumab for treating chronic lymphocytic leukemia","volume":"13","author":"Luan","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb1005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2023.103404_bb1010","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.4049\/jimmunol.165.10.5970","article-title":"Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus","volume":"165","author":"Odendahl","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2023.103404_bb1015","series-title":"Mechanisms of Lymphocyte Activation and Immune Regulation X","first-page":"125","article-title":"Role of the CD19 and CD21\/35 receptor complex in innate immunity, host defense and autoimmunity","author":"Haas","year":"2005"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb1020","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb1025","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb1030","first-page":"91","article-title":"Complement in lupus nephritis: new perspectives","volume":"1","author":"Bao","year":"2015","journal-title":"Kidney Dis (Basel, Switzerland)"},{"issue":"February","key":"10.1016\/j.autrev.2023.103404_bb1035","article-title":"Update on the cellular and molecular aspects of lupus nephritis","volume":"216","author":"Frangou","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2023.103404_bb1040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fimmu.2016.00055","article-title":"Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway","volume":"7","author":"Macedo","year":"2016","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2023.103404_bb1045","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/j.ekir.2021.06.016","article-title":"Complement in Lupus: Biomarker, Therapeutic Target, or a Little Bit of Both?","volume":"6","author":"Cantarelli","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1016\/j.autrev.2023.103404_bb1050","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00296-017-3686-5","article-title":"Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence","volume":"37","author":"Sciascia","year":"2017","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.autrev.2023.103404_bb1055","doi-asserted-by":"crossref","first-page":"103055","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the \u201cCAPS Registry\u201d","volume":"21","author":"L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.autrev.2023.103404_bb1060","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1097\/01.TP.0000164159.20075.16","article-title":"Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways","volume":"79","author":"Zand","year":"2005","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb1065","first-page":"689","article-title":"Antilymphocyte globulin in the treatment of a patient with diffuse proliferative lupus nephritis","volume":"63","author":"Izzi","year":"1978","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb1070","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1191\/0961203304lu1027oa","article-title":"Autologous stem cell transplantation for systemic lupus erythematosus","volume":"13","author":"Jayne","year":"2004","journal-title":"Lupus."},{"key":"10.1016\/j.autrev.2023.103404_bb1075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13223-019-0373-y","article-title":"Haemopoietic stem cell transplantation in Systemic lupus erythematosus: a systematic review","volume":"15","author":"de Silva","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2023.103404_bb1080","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2215\/CJN.10570918","article-title":"Autologous hematopoietic stem cell transplantation for refractory lupus nephritis","volume":"14","author":"Huang","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb1085","doi-asserted-by":"crossref","first-page":"105523","DOI":"10.1016\/j.jbspin.2023.105523","article-title":"New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review","volume":"90","author":"Felten","year":"2023","journal-title":"Jt Bone Spine"},{"issue":"10381","key":"10.1016\/j.autrev.2023.103404_bb1090","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2023.103404_bb1095","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.autrev.2023.103404_bb1100","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.autrev.2023.103404_bb1105","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103404_bb1110","doi-asserted-by":"crossref","first-page":"102738","DOI":"10.1016\/j.autrev.2020.102738","article-title":"The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts\u2019","volume":"20","author":"Giacomelli","year":"2021","journal-title":"Consensus Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2023.103404_bb1115","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","volume":"78","author":"Humby","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223001386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:28:39Z","timestamp":1761600519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223001386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":223,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1568997223001386"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103404","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From systemic lupus erythematosus to lupus nephritis: The evolving road to targeted therapies","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103404","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103404"}}